Home › Funds › Bain Capital Life Sciences Investors, LLC › DYN
Bain Capital Life Sciences Investors, LLC position in DYN
DYNE THERAPEUTICS INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 1,900,000 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$30.6M, representing 2.11% of its reported portfolio and ranking #13 among its reported holdings. Bain Capital Life Sciences Investors, LLC first reported this position in Q3 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's DYN position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in DYN in Q3 2026 at 1,900,000 shares (US$30.6M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 1.90M | $30.61M | New |
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$75.0M), TCG Crossover Management, LLC (US$74.3M), ORBIMED ADVISORS LLC (US$71.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Vestal Point Capital, LP 3.38M sh · $74.96M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $74.35M · Q3 2026
- ORBIMED ADVISORS LLC 3.24M sh · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M sh · $70.03M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.69M sh · $59.73M · Q2 2026
- FCPM III SERVICES B.V. 3.59M sh · $57.78M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 3.44M sh · $55.43M · Q3 2026
- Logos Global Management LP 3.00M sh · $48.33M · Q3 2026
- Venrock Adviser, LLC 2.17M sh · $48.28M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.68M sh · $43.14M · Q3 2026
- MPM BioImpact LLC 1.92M sh · $42.69M · Q2 2026
- Sofinnova Investments, Inc. 2.51M sh · $40.45M · Q3 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held DYN?
Bain Capital Life Sciences Investors, LLC has disclosed DYN holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Bain Capital Life Sciences Investors, LLC's current position in DYN?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 1.90M shares of DYN (DYNE THERAPEUTICS INC), valued at $30.61M, representing 2.11% of its reported portfolio and ranking #13.
Has Bain Capital Life Sciences Investors, LLC been buying or selling DYN?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC newly opened its position in DYN.
Which other funds hold DYN?
Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, ORBIMED ADVISORS LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.